Mesoblast Limited Shoots to a 4-Year High as Celgene Invests $45 Million

MELBOURNE, Australia and NEW YORK, April 12, 2015 -- Mesoblast Limited today announced that the Company has entered into an Agreement with US-based Celgene Corporation, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Pursuant to this Agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.

http://www.biospace.com/news_story.aspx?StoryID=371993&full=1